384 related articles for article (PubMed ID: 29663836)
1. Computational modeling of human oral bioavailability: what will be next?
Cabrera-Pérez MÁ; Pham-The H
Expert Opin Drug Discov; 2018 Jun; 13(6):509-521. PubMed ID: 29663836
[TBL] [Abstract][Full Text] [Related]
2. Physiologically Based Pharmacokinetic Modeling in Lead Optimization. 1. Evaluation and Adaptation of GastroPlus To Predict Bioavailability of Medchem Series.
Daga PR; Bolger MB; Haworth IS; Clark RD; Martin EJ
Mol Pharm; 2018 Mar; 15(3):821-830. PubMed ID: 29337578
[TBL] [Abstract][Full Text] [Related]
3. PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach.
Poulin P; Jones RD; Jones HM; Gibson CR; Rowland M; Chien JY; Ring BJ; Adkison KK; Ku MS; He H; Vuppugalla R; Marathe P; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Yates JW
J Pharm Sci; 2011 Oct; 100(10):4127-57. PubMed ID: 21541937
[TBL] [Abstract][Full Text] [Related]
4. Structure-ADME relationship: still a long way to go?
Hou T; Wang J
Expert Opin Drug Metab Toxicol; 2008 Jun; 4(6):759-70. PubMed ID: 18611116
[TBL] [Abstract][Full Text] [Related]
5. Improving on in-silico prediction of oral drug bioavailability.
Alqahtani S
Expert Opin Drug Metab Toxicol; 2023; 19(10):665-670. PubMed ID: 37728393
[TBL] [Abstract][Full Text] [Related]
6. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: prediction of plasma concentration-time profiles in human from in vivo preclinical data by using the Wajima approach.
Vuppugalla R; Marathe P; He H; Jones RD; Yates JW; Jones HM; Gibson CR; Chien JY; Ring BJ; Adkison KK; Ku MS; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Poulin P
J Pharm Sci; 2011 Oct; 100(10):4111-26. PubMed ID: 21480234
[TBL] [Abstract][Full Text] [Related]
7. Physiologically Based Pharmacokinetic Modeling in Lead Optimization. 2. Rational Bioavailability Design by Global Sensitivity Analysis To Identify Properties Affecting Bioavailability.
Daga PR; Bolger MB; Haworth IS; Clark RD; Martin EJ
Mol Pharm; 2018 Mar; 15(3):831-839. PubMed ID: 29337562
[TBL] [Abstract][Full Text] [Related]
8. IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 4: Prediction accuracy and software comparisons with improved data and modelling strategies.
Ahmad A; Pepin X; Aarons L; Wang Y; Darwich AS; Wood JM; Tannergren C; Karlsson E; Patterson C; Thörn H; Ruston L; Mattinson A; Carlert S; Berg S; Murphy D; Engman H; Laru J; Barker R; Flanagan T; Abrahamsson B; Budhdeo S; Franek F; Moir A; Hanisch G; Pathak SM; Turner D; Jamei M; Brown J; Good D; Vaidhyanathan S; Jackson C; Nicolas O; Beilles S; Nguefack JF; Louit G; Henrion L; Ollier C; Boulu L; Xu C; Heimbach T; Ren X; Lin W; Nguyen-Trung AT; Zhang J; He H; Wu F; Bolger MB; Mullin JM; van Osdol B; Szeto K; Korjamo T; Pappinen S; Tuunainen J; Zhu W; Xia B; Daublain P; Wong S; Varma MVS; Modi S; Schäfer KJ; Schmid K; Lloyd R; Patel A; Tistaert C; Bevernage J; Nguyen MA; Lindley D; Carr R; Rostami-Hodjegan A
Eur J Pharm Biopharm; 2020 Nov; 156():50-63. PubMed ID: 32805361
[TBL] [Abstract][Full Text] [Related]
9. PBPK models for the prediction of in vivo performance of oral dosage forms.
Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J
Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672
[TBL] [Abstract][Full Text] [Related]
10. An update on the potential role of intestinal first-pass metabolism for the prediction of drug-drug interactions: the role of PBPK modeling.
Alqahtani S; Bukhari I; Albassam A; Alenazi M
Expert Opin Drug Metab Toxicol; 2018 Jun; 14(6):625-634. PubMed ID: 29806951
[TBL] [Abstract][Full Text] [Related]
11. Prediction of the human oral bioavailability by using in vitro and in silico drug related parameters in a physiologically based absorption model.
Paixão P; Gouveia LF; Morais JA
Int J Pharm; 2012 Jun; 429(1-2):84-98. PubMed ID: 22449410
[TBL] [Abstract][Full Text] [Related]
12. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 1: goals, properties of the PhRMA dataset, and comparison with literature datasets.
Poulin P; Jones HM; Jones RD; Yates JW; Gibson CR; Chien JY; Ring BJ; Adkison KK; He H; Vuppugalla R; Marathe P; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Ku MS
J Pharm Sci; 2011 Oct; 100(10):4050-73. PubMed ID: 21523782
[TBL] [Abstract][Full Text] [Related]
13. Current status and future opportunities for incorporation of dissolution data in PBPK modeling for pharmaceutical development and regulatory applications: OrBiTo consortium commentary.
Jamei M; Abrahamsson B; Brown J; Bevernage J; Bolger MB; Heimbach T; Karlsson E; Kotzagiorgis E; Lindahl A; McAllister M; Mullin JM; Pepin X; Tistaert C; Turner DB; Kesisoglou F
Eur J Pharm Biopharm; 2020 Oct; 155():55-68. PubMed ID: 32781025
[TBL] [Abstract][Full Text] [Related]
14. An update on computational oral absorption simulation.
Dressman JB; Thelen K; Willmann S
Expert Opin Drug Metab Toxicol; 2011 Nov; 7(11):1345-64. PubMed ID: 21939427
[TBL] [Abstract][Full Text] [Related]
15. IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 2: An introduction to the simulation exercise and overview of results.
Margolskee A; Darwich AS; Pepin X; Aarons L; Galetin A; Rostami-Hodjegan A; Carlert S; Hammarberg M; Hilgendorf C; Johansson P; Karlsson E; Murphy D; Tannergren C; Thörn H; Yasin M; Mazuir F; Nicolas O; Ramusovic S; Xu C; Pathak SM; Korjamo T; Laru J; Malkki J; Pappinen S; Tuunainen J; Dressman J; Hansmann S; Kostewicz E; He H; Heimbach T; Wu F; Hoft C; Laplanche L; Pang Y; Bolger MB; Huehn E; Lukacova V; Mullin JM; Szeto KX; Costales C; Lin J; McAllister M; Modi S; Rotter C; Varma M; Wong M; Mitra A; Bevernage J; Biewenga J; Van Peer A; Lloyd R; Shardlow C; Langguth P; Mishenzon I; Nguyen MA; Brown J; Lennernäs H; Abrahamsson B
Eur J Pharm Sci; 2017 Jan; 96():610-625. PubMed ID: 27816631
[TBL] [Abstract][Full Text] [Related]
16. Advances in Predictions of Oral Bioavailability of Candidate Drugs in Man with New Machine Learning Methodology.
Fagerholm U; Hellberg S; Spjuth O
Molecules; 2021 Apr; 26(9):. PubMed ID: 33925103
[TBL] [Abstract][Full Text] [Related]
17. Prediction of Oral Bioavailability in Rats: Transferring Insights from in Vitro Correlations to (Deep) Machine Learning Models Using in Silico Model Outputs and Chemical Structure Parameters.
Schneckener S; Grimbs S; Hey J; Menz S; Osmers M; Schaper S; Hillisch A; Göller AH
J Chem Inf Model; 2019 Nov; 59(11):4893-4905. PubMed ID: 31714067
[TBL] [Abstract][Full Text] [Related]
18.
Kamiya Y; Handa K; Miura T; Yanagi M; Shigeta K; Hina S; Shimizu M; Kitajima M; Shono F; Funatsu K; Yamazaki H
Chem Res Toxicol; 2021 Feb; 34(2):507-513. PubMed ID: 33433197
[TBL] [Abstract][Full Text] [Related]
19. ADME evaluation in drug discovery. 6. Can oral bioavailability in humans be effectively predicted by simple molecular property-based rules?
Hou T; Wang J; Zhang W; Xu X
J Chem Inf Model; 2007; 47(2):460-3. PubMed ID: 17381169
[TBL] [Abstract][Full Text] [Related]
20. Prediction of drug disposition on the basis of its chemical structure.
Stepensky D
Clin Pharmacokinet; 2013 Jun; 52(6):415-31. PubMed ID: 23463353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
